Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y6Q6
UPID:
TNR11_HUMAN
Alternative names:
Osteoclast differentiation factor receptor; Receptor activator of NF-KB
Alternative UPACC:
Q9Y6Q6; I4EC36; I4EC38; I4EC39; I7JE63; N0GVH0; Q59EP9
Background:
Tumor necrosis factor receptor superfamily member 11A, also known as the receptor activator of NF-KB and osteoclast differentiation factor receptor, plays a pivotal role in bone remodeling and immune system regulation. It serves as a receptor for TNFSF11/RANKL/TRANCE/OPGL, crucial for RANKL-mediated osteoclastogenesis, facilitating osteoclast development and function. This protein's interaction with EEIG1 enhances osteoclastogenesis by promoting NFATC1 transcription and activating PLCG2.
Therapeutic significance:
The protein's involvement in diseases such as Familial expansile osteolysis, early-onset Paget disease of bone 2, and autosomal recessive osteopetrosis 7 highlights its therapeutic potential. Targeting this protein could lead to innovative treatments for these bone disorders, offering hope for patients suffering from these debilitating conditions.